Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer.
Seung-Hyuk ShimJung-Yun LeeYoo Young LeeJeong-Yeol ParkJung-Yun LeeSe Ik KimGwan Hee HanEun-Jung YangJoseph J NohGa Won YimJoo Hyuk SonNam Kyeong KimTae-Hyun KimTae Wook KongYoun Jin ChoiAngela ChoHyunji LimEun Bi JangHyun Woong ChoDong Hoon SuhPublished in: Journal of gynecologic oncology (2024)
In the 2023 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Endometrial cancer: immune checkpoint inhibitor, antibody drug conjugates (ADCs), selective inhibitor of nuclear export, CDK4/6 inhibitors WEE1 inhibitor, poly (ADP-ribose) polymerase (PARP) inhibitors. 2) Cervical cancer: surgery in low-risk early-stage cervical cancer, therapy for locally advanced stage and advanced, metastatic, or recurrent setting; and 3) Ovarian cancer: immunotherapy, triplet therapies using immune checkpoint inhibitors along with antiangiogenic agents and PARP inhibitors, and ADCs. In 2023, the field of endometrial cancer treatment witnessed a landmark year, marked by several practice-changing outcomes with immune checkpoint inhibitors and the reliable efficacy of PARP inhibitors and ADCs.
Keyphrases
- endometrial cancer
- cancer therapy
- early stage
- dna damage
- dna repair
- palliative care
- squamous cell carcinoma
- small cell lung cancer
- primary care
- minimally invasive
- drug delivery
- radiation therapy
- type diabetes
- coronary artery bypass
- cell cycle
- skeletal muscle
- neoadjuvant chemotherapy
- percutaneous coronary intervention
- locally advanced
- insulin resistance
- quantum dots
- surgical site infection